Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics Inc (NASDAQ: PSTV) is a clinical-stage biopharmaceutical company pioneering targeted radiotherapeutics for challenging cancers. This news hub provides investors and medical professionals with essential updates on clinical trials, regulatory developments, and strategic partnerships.
Access timely reports on PSTV's innovative CNS cancer therapies including rhenium (186Re) obisbemeda for glioblastoma and leptomeningeal metastases. Track progress across multiple development stages while staying informed about financial updates and manufacturing collaborations that support the company's pipeline.
Our curated collection features earnings announcements, trial result disclosures, FDA communications, and partnership expansions. All content is verified through primary sources to ensure accuracy for investment research and clinical practice decisions.
Bookmark this page for streamlined access to PSTV's latest scientific advancements and corporate developments. Check regularly for critical updates impacting the neuro-oncology treatment landscape and the company's position within precision radiotherapy markets.
Plus Therapeutics, Inc. (PSTV) announced the successful treatment of the first patient in the eighth cohort of their Phase 1 ReSPECT™-GBM clinical trial for recurrent glioblastoma. This cohort features a 40% increase in treatment volume and radioactivity compared to previous cohorts. To date, 22 patients have been treated across eight cohorts with no dose-limiting toxicities reported. The trial is progressing as scheduled, and an update is expected in Q4 2021.
Plus Therapeutics (PSTV) announced it will report its second quarter 2021 financial results on July 22, 2021, after market close. A conference call and webcast to discuss the results and provide a corporate update will follow at 5:00 p.m. ET. Plus Therapeutics focuses on developing targeted radiotherapeutics for rare cancers, utilizing a nanotechnology platform for drug delivery and formulation. This innovative approach aims to enhance the safety and efficacy of treatments for difficult-to-treat cancers.
Plus Therapeutics (PSTV) announced a significant step forward in their ReSPECT™ trial for Rhenium NanoLiposome (RNL™) in treating recurrent glioblastoma (GBM). The Data and Safety Monitoring Board has approved advancing to the eighth cohort, which will feature a 40% increase in total radioactivity, escalating the infused dose to 31.2 millicuries. RNL™ has demonstrated a favorable safety profile with no dose-limiting toxicities observed in the first seven cohorts, treating 21 patients. The trial is supported by the NIH/National Cancer Institute at three U.S. sites.
Plus Therapeutics (PSTV) announced a poster presentation at the 6th Biennial Pediatric Neuro-Oncology Research Conference. The poster focuses on a Phase I study of Rhenium-186 Nanoliposomes (186RNL) for treating ependymoma and high-grade glioma. Dr. Ashley S. Plant-Fox from Northwestern University leads the presentation. The FDA has provided positive feedback on their study synopsis and confirmed no additional toxicology studies are needed for pediatric trials. RNL has also received Orphan Drug and Fast Track designations for glioblastoma treatment.
AUSTIN, Texas, June 9, 2021 – Plus Therapeutics (Nasdaq: PSTV) has announced that President and CEO Marc H. Hedrick M.D. will participate in the BIO Digital Conference on June 10-11 and 14-18, 2021. The conference presentation will be accessible on-demand on the conference website. Following the event, it will also be available in the Investors section of Plus Therapeutics' website. The company focuses on nanoliposome-encapsulated radionuclides for cancer treatment, enhancing drug delivery and efficacy for rare cancers.
Plus Therapeutics (PSTV) announced two collaboration agreements aimed at advancing the cGMP manufacturing processes for Rhenium NanoLiposome (RNL™), targeting recurrent glioblastoma. The partnerships include Invicro LLC for process development and imaging support, and Eurofins BioPharma for developing test methods for purity and compliance. These agreements are crucial for progressing RNL™ to registrational clinical trials and eventual commercial supply, according to CEO Marc H. Hedrick. Previous agreements include a master services engagement with Piramal Pharma Solutions for RNL™ production.
Plus Therapeutics, Inc. (Nasdaq: PSTV) reported first-quarter financial results for 2021, highlighting a cash balance of $14.4 million, up from $8.3 million at year-end 2020. The company posted a net loss of $2.7 million, or $(0.33) per share, compared to a net loss of $1.1 million, or $(0.28) per share, in Q1 2020. Key developments include advancements in their lead drug Rhenium NanoLiposome (RNL™) for treating rare cancers, and progress in clinical trials, including treatment for recurrent glioblastoma and upcoming FDA meetings. A conference call is scheduled for April 22, 2021, at 5:00 p.m. ET.
Plus Therapeutics (Nasdaq: PSTV), a clinical-stage pharmaceutical company focused on therapies for rare cancers, will report its first quarter 2021 financial results on April 22, 2021, after market close. Following the earnings announcement, a conference call and webcast will take place at 5:00 PM ET to discuss results and provide a corporate update. Plus Therapeutics utilizes a unique nanotechnology platform aimed at enhancing drug delivery and efficacy for difficult-to-treat cancers. Details for the conference call and webcast are available on their website.
Plus Therapeutics (Nasdaq: PSTV) has signed a master services agreement (MSA) with Piramal Pharma Solutions for the development of its Rhenium NanoLiposome (RNL™), aimed at treating rare cancers, including glioblastoma. The agreement entails transferring analytical and microbiological methods, production processes, and stability studies, executed at Piramal's facility in Lexington, Kentucky. This partnership is expected to pave the way for future clinical and commercial supply agreements. The collaboration marks a significant milestone in advancing RNL towards regulatory approval.
Plus Therapeutics (Nasdaq: PSTV) announced that CEO Marc Hedrick will present at two upcoming virtual conferences. The first event is the BIO-Europe Spring Digital 2021 from March 22-25, with presentations available on demand starting March 22. The second event is the Q1 Virtual Investor Summit, taking place March 23-25, with a scheduled presentation on March 23 at 11:30 a.m. ET. Investors interested in meetings should contact conference coordinators. Webcasts will be available on Plus Therapeutics' website under 'Events' in the Investor Relations section.
